Human Cytomegalovirus and Autoimmune Disease

被引:88
作者
Halenius, Anne [1 ]
Hengel, Hartmut [1 ]
机构
[1] Univ Freiburg, Inst Virol, Univ Med Ctr, D-79104 Freiburg, Germany
关键词
SYSTEMIC-LUPUS-ERYTHEMATOSUS; EPSTEIN-BARR-VIRUS; NECROSIS-FACTOR-ALPHA; CD4+CD28-AND CD8+CD28-T CELLS; CD4(+)CD28(-) T-CELLS; LATE PROTEIN UL94; GENE-PRODUCT; MULTIPLE-SCLEROSIS; MOLECULAR MIMICRY; RHEUMATOID-ARTHRITIS;
D O I
10.1155/2014/472978
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Human cytomegalovirus (HCMV) represents a prototypic pathogenic member of the beta-subgroup of the herpesvirus family. Arange of HCMV features like its lytic replication in multiple tissues, the lifelong persistence through periods of latency and intermitting reactivation, the extraordinary large proteome, and extensive manipulation of adaptive and innate immunity make HCMV a high profile candidate for involvement in autoimmune disorders. We surveyed the available literature for reports on HCMV association with onset or exacerbation of autoimmune disease. A causative linkage between HCMV and systemic lupus erythematosus (SLE), systemic sclerosis (SSc), diabetes mellitus type 1, and rheumatoid arthritis (RA) is suggested by the literature. However, a clear association of HCMV seroprevalence and disease could not be established, leaving the question open whether HCMV could play a coresponsible role for onset of disease. For convincing conclusions population-based prospective studies must be performed in the future. Specific immunopathogenic mechanisms by which HCMV could contribute to the course of autoimmune disease have been suggested, for example, molecular mimicry by UL94 in SSc and UL83/pp65 in SLE patients, as well as aggravation of joint inflammation by induction and expansion of CD4+/CD28-T-cells in RA patients. Further studies are needed to validate these findings and to lay the grounds for targeted therapeutic intervention.
引用
收藏
页数:15
相关论文
共 171 条
[51]   A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter [J].
Hengel, H ;
Koopmann, JO ;
Flohr, T ;
Muranyi, W ;
Goulmy, E ;
Hammerling, GJ ;
Koszinowski, UH ;
Momburg, F .
IMMUNITY, 1997, 6 (05) :623-632
[52]   Cytomegalovirus in autoimmunity: T cell crossreactivity to viral antigen and autoantigen glutamic acid decarboxylase [J].
Hiemstra, HS ;
Schloot, NC ;
van Veelen, PA ;
Willemen, SJM ;
Franken, KLMC ;
van Rood, JJ ;
de Vries, RRP ;
Chaudhuri, A ;
Behan, PO ;
Drijfhout, JW ;
Roep, BO .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (07) :3988-3991
[53]  
HILTUNEN M, 1995, DIABETOLOGIA, V38, P705, DOI 10.1007/s001250050341
[54]  
Hooper M, 1999, J RHEUMATOL, V26, P1452
[55]   Pancreatic expression of interferon-γ protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis [J].
Horwitz, MS ;
La Cava, A ;
Fine, C ;
Rodriguez, E ;
Ilic, A ;
Sarvetnick, N .
NATURE MEDICINE, 2000, 6 (06) :693-697
[56]   Fragment of tegument protein pp65 of human cytomegalovirus induces autoantibodies in BALB/c mice [J].
Hsieh, Ao-Ho ;
Jhou, Yi-Jyun ;
Liang, Chung-Ting ;
Chang, Mingi ;
Wang, Shih-Lien .
ARTHRITIS RESEARCH & THERAPY, 2011, 13 (05)
[57]   Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis [J].
Hu, PQ ;
Fertig, N ;
Medsger, TA ;
Wright, TA .
ARTHRITIS AND RHEUMATISM, 2003, 48 (05) :1363-1373
[58]   THE PREVALENCE OF TYPE-1 DIABETES-MELLITUS AT FOLLOW-UP OF SWEDISH INFANTS CONGENITALLY INFECTED WITH CYTOMEGALOVIRUS [J].
IVARSSON, SA ;
LINDBERG, B ;
NILSSON, KO ;
AHLFORS, K ;
SVANBERG, L .
DIABETIC MEDICINE, 1993, 10 (06) :521-523
[59]   An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus [J].
James, JA ;
Kaufman, KM ;
Farris, AD ;
Taylor-Albert, E ;
Lehman, TJA ;
Harley, JB .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (12) :3019-3026
[60]  
James JA, 2001, ARTHRITIS RHEUM-US, V44, P1122, DOI 10.1002/1529-0131(200105)44:5<1122::AID-ANR193>3.3.CO